Clinical Trials on Wet Age Related Macular Degeneration

Total 6409 results

Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
AbbVie

Completed

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Withdrawn

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (CANARI)

Wet Age-related Macular Degeneration (Wet AMD)
AbbVie
AbbVie

Enrolling by invitation

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Gene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMD

United States
Caregen Co. Ltd.
CBCC Global Research

Not yet recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Age-related Wet Macular Degeneration

United States
REGENXBIO Inc.

Completed

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Hoffmann-La Roche

Withdrawn

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (Diagrid)

Neovascular Age-Related Macular Degeneration

Denmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
Novartis Pharmaceuticals

Terminated

Russian Registry of Patients With nAMD

Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals

Completed

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Neovascular Age Related Macular Degeneration

United States
RemeGen Co., Ltd.

Recruiting

Efficacy and Safety of RC28-E Versus Aflibercept

Wet Age-related Macular Degeneration

China
Sinocelltech Ltd.

Recruiting

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Wet Age-related Macular Degeneration

China
EyePoint Pharmaceuticals, Inc.

Active, not recruiting

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (DAVIO2)

Wet Age-related Macular Degeneration

United States
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
EyePoint Pharmaceuticals, Inc.

Completed

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

Wet Age-related Macular Degeneration

United States
Bayer

Completed

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration

India
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Alkahest, Inc.

Completed

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Qilu Pharmaceutical Co., Ltd.

Completed

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Wet Age-related Macular Degeneration

China
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Completed

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Maculopathy, Age-Related

United States
Hoffmann-La Roche

Recruiting

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration | nAMD

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration

China
Hoffmann-La Roche

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal)

Neovascular Age-Related Macular Degeneration

Belgium, United States, Italy, Argentina, Spain, United Kingdom, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
Hoffmann-La Roche

Completed

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Neovascular Age-Related Macular Degeneration

United States
First Affiliated Hospital of Chongqing Medical...

Enrolling by invitation

Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD (IIT-A)

Exudative Age-Related Macular Degeneration

China
Novartis Pharmaceuticals

Completed

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Iconic Therapeutics, Inc.

Completed

Safety and Tolerability Study for Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Huabo Biopharm Co., Ltd.

Completed

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Duke University
Bausch & Lomb Incorporated

Completed

Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD

Neovascular Age-Related Macular Degeneration

United States
Subhransu K. Ray, M.D., Ph.D.
Bay Area Retina Associates

Completed

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD (Lucedex)

Exudative Age-Related Macular Degeneration

United States
Sheba Medical Center
Universitaire Ziekenhuizen KU Leuven

Unknown

The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) (AMD)

Neovascular Age Related Macular Degeneration

Belgium, Israel
Oraya Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)

Macular Degeneration | Age-related Macular Degeneration | AMD | Wet AMD | Wet Age-related Macular Degeneration

United Kingdom, Italy
Ocular Therapeutix, Inc.
Duke University; Fortrea

Recruiting

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Neovascular Age-Related Macular Degeneration

China
Ocular Therapeutix, Inc.

Completed

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) (PEREGRINE)

Age-related Macular Degeneration (AMD)
Apellis Pharmaceuticals, Inc.

Completed

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD (ASAP II)

Neovascular Age-Related Macular Degeneration

United States, Australia
Retina Macula Institute

Completed

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Johns Hopkins University

Completed

NVAMD Satellite Study

Neovascular Age Related Macular Degeneration

United States
Alcon Research

Completed

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Exudative Age-Related Macular Degeneration
Alcon Research

Completed

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

Exudative Age-Related Macular Degeneration
Peking University People's Hospital

Completed

Bevacizumab for Neovascular Age-related Macular Degeneration

Exudative Age-related Macular Degeneration

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Wet Age-related Macular Degeneration

China
Ophthotech Corporation

Completed

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Wet Age-related Macular Degeneration

United States, Hungary, Latvia
Bayer
Regeneron Pharmaceuticals

Completed

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)

Wet Age-related Macular Degeneration

Switzerland

3

Subscribe